Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2020-06-08 Regulatory Filings
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Biotest's Zutectra(R) demonstrates improved quality of life in a study with liver transplant patients
Regulatory Filings Classification · 99% confidence The document is titled 'News Details' and begins with a date and a headline about a research update ('Key word(s): Research Update'). It details the results of a clinical study regarding the product Zutectra(R) and its impact on patient quality of life. It includes sections like 'PRESS RELEASE', 'About Zutectra(R)', and contact information for IR/PR. The footer explicitly mentions 'DGAP-News' and 'DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.' This structure strongly indicates a press release announcing new research findings, which is a form of corporate news. Since there is no specific category for a 'Research Update Press Release' and it is not a full financial report (10-K, IR), nor a management/board change (MANG), the most appropriate general category for a non-standard corporate announcement distributed via a news service is 'Regulatory Filings' (RNS), as it serves as a general regulatory/corporate news dissemination channel when other specific codes do not apply. It is not an Earnings Release (ER) as it focuses on clinical data, not period financial results.
2020-06-08 English
Biotest AG: Biotest achieves significant milestone by completing phase I/III clinical trial with fibrinogen
Legal Proceedings Report Classification · 99% confidence The document is a press release dated May 26, 2020, announcing a 'significant milestone' regarding the completion of a Phase I/III clinical trial for a fibrinogen concentrate. It details research updates, efficacy/safety confirmation, and future steps for regulatory approval. This content strongly aligns with reporting on research and development progress, which is often released as an Earnings Release (ER) or a general Regulatory Filing (RNS) if it doesn't fit a more specific category. Since it is a specific announcement about clinical trial progress and results (even if preliminary), and not a full financial report (10-K, IR) or a management discussion (MDA), it fits best as an Earnings Release (ER) which often includes key operational/research highlights, or potentially RNS as a general regulatory news item. Given the focus on clinical trial completion and initial results, which are key operational milestones often highlighted during earnings cycles, ER is a strong candidate. However, since it is primarily a research update announcement rather than a summary of financial performance for a period, and it is disseminated via DGAP (a regulatory news service), it functions as a general corporate announcement. Comparing the options, 'ER' (Earnings Release) is for financial results highlights, and 'RNS' (Regulatory Filings) is the general fallback. Since this is a specific operational/R&D update, and not a financial summary, 'RNS' is the most appropriate general category for non-standard corporate news dissemination, although 'ER' often encompasses such operational news if tied to a reporting period. Given the context of clinical trial completion, it is a significant corporate event announcement. I will classify it as RNS as it is a general regulatory news dissemination via DGAP that doesn't perfectly match ER (which usually focuses on revenue/profit).
2020-05-26 English
Datum:14.05.2020
Audit Report / Information Classification · 100% confidence The document is a 'Bestätigungsvermerk des unabhängigen Abschlussprüfers' (Independent Auditor's Report) for Biotest Aktiengesellschaft for the fiscal year 2019. It details the audit of the annual financial statements (Jahresabschluss) and the management report (Lagebericht) in accordance with German commercial law (HGB). Since it is a standalone audit report and not the full annual report itself, it falls under the 'Audit Report / Information' category. FY 2019
2020-05-14 German
Biotest AG: Annual General Meeting approves dividend distribution
AGM Information Classification · 99% confidence The document is a press release dated May 8, 2020, explicitly titled "Biotest AG: Annual General Meeting approves dividend distribution." It details resolutions passed at the "first ordinary, virtual Annual General Meeting on 08 May 2020," specifically mentioning the approval of a dividend distribution and the approval of actions by the Executive Board and Supervisory Board. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the most appropriate classification is AGM Information (AGM-R). Although it mentions dividend distribution (DIV), the primary context is the meeting itself.
2020-05-08 English
Biotest AG: Biotest increases sales by 26%
Earnings Release Classification · 100% confidence The document is a press release dated May 8, 2020, titled "Biotest increases sales by 26%" and explicitly mentions "Quarter Results" as a keyword. It details revenue (€ 97.7 million) and EBIT for the first three months of 2020, which constitutes a financial report for a period shorter than a year (Q1 2020). This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). Although it mentions where the full 'Quarterly statement' is available, the content provided is the summary release of the results, not just an announcement of the report's publication. Q1 2020
2020-05-08 English
Q1 statement / Q1 financial report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the period ending 31 March 2020. It contains detailed financial statements (Consolidated statement of income, financial position, cash flow), segment reporting, and management analysis of business performance. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2020
2020-05-08 German

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.